Pinch-zoom for details.
The offering
Price range
$8–$10
per share
Shares offered
5.56M
+833K over-allotment option
Raise at $9 midpoint
$50.0M
5,555,555 × $9, before fees
What the company does
Late clinical-stage drug developer for inflammatory eye diseases that can cause blindness.
Things to weigh
- The filing's financial tables couldn't be read reliably, so none are shown here.
Risks
- We are a clinical stage pharmaceutical company and we have incurred significant losses since our inception and anticipate…
- We do not believe that our current cash on hand will be sufficient to fund our projected operating requirements
- Even if this offering is successful, we expect that we will need to raise substantial additional funding before we can expect to complete the…
- We depend substantially on the success of our product candidates and their clinical trials
- Our prior phase 3 trial did not meet its primary endpoint (ACC = 0), and future trials may also fail…
- Clinical drug development is a lengthy and expensive process with uncertain timelines and uncertain outcomes
The filing's own risk-factor headings, shortened.
Strategy
- Completing development and obtaining approval of TRS01 for the treatment of non -infectious anterior uveitis…
- Launching focused marketing activities to commercialize TRS01 in the U.S. using a staged commercialization approach
- Post launch, broadening the label of TRS01
- Launch outside the United States
- Developing TRS02 for additional indications associated with uveitis and other back -of - the-eye ocular inflammatory diseases
The filing's own strategy headings, shortened.
Source: Tarsier Pharma Ltd.'s Form F-1/A, filed with the SEC on Jul 16, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.